Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6

2001 ◽  
Vol 355 (2) ◽  
pp. 373-379 ◽  
Author(s):  
Graham P. HAYHURST ◽  
Jacky HARLOW ◽  
Joey CHOWDRY ◽  
Esme GROSS ◽  
Emma HILTON ◽  
...  

Homology models of the active site of cytochrome P450 2D6 (CYP2D6) have identified phenylalanine 481 (Phe481) as a putative ligand-binding residue, its aromatic side chain being potentially capable of participating in π-π interactions with the benzene ring of ligands. We have tested this hypothesis by replacing Phe481 with tyrosine (Phe481 → Tyr), a conservative substitution, and with leucine (Phe481 → Leu) or glycine (Phe481 → Gly), two non-aromatic residues, and have compared the properties of the wild-type and mutant enzymes in microsomes prepared from yeast cells expressing the appropriate cDNA-derived protein. The Phe481 → Tyr substitution did not alter the kinetics [Km (µM) and Vmax (pmol/min per pmol) respectively] of oxidation of S-metoprolol (27; 4.60), debrisoquine (46; 2.46) or dextromethorphan (2; 8.43) relative to the respective wild-type values [S-metoprolol (26; 3.48), debrisoquine (51; 3.20) and dextromethorphan (2; 8.16)]. The binding capacities [Ks (µM)] of a range of CYP2D6 ligands to the Phe481 → Tyr enzyme (S-metoprolol, 22.8; debrisoquine, 12.5; dextromethorphan, 2.3; quinidine, 0.13) were also similar to those for the wild-type enzyme (S-metoprolol, 10.9; debrisoquine, 8.9; dextromethorphan, 3.1; quinidine, 0.10). In contrast, the Phe481 → Leu and Phe481 → Gly substitutions increased significantly (3-16-fold) the Km values of oxidation of the three substrates [S-metoprolol (120-124µM), debrisoquine (152-184µM) and dextromethorphan (20-31µM)]. Similarly, the Ks values of the ligands to Phe481 → Leu and Phe481 → Gly mutants were also increased 3 to 10-fold (S-metoprolol, 33.2-41.9µM; debrisoquine, 85-90µM; dextromethorphan, 15.7-18.8µM; quinidine 0.35-0.53µM). However, contrary to a recent proposal that Phe481 has the dominant role in the binding of substrates that undergo CYP2D6-mediated N-dealkylation routes of metabolism, the Phe481 → Gly substitution did not substantially decrease the capacity of the enzyme to N-deisopropylate metoprolol (wild-type, 1.12pmol/min per pmol of P450; Phe481 → Gly, 0.71), whereas an Asp301 → Gly substitution decreased the N-dealkylation reaction by 95% of the wild-type rate. Overall, our results are consistent with the proposal that Phe481 is a ligand-binding residue in the active site of CYP2D6 and that the residue interacts with ligands via a π-π interaction between its phenyl ring and the aromatic moiety of the ligand. However, the relative importance of Phe481 in binding is ligand-dependent; furthermore, its importance is secondary to that of Asp301. Finally, contrary to predictions of a recent homology model, Phe481 does not seem to have a primary role in CYP2D6-mediated N-dealkylation.

2000 ◽  
Vol 345 (3) ◽  
pp. 565 ◽  
Author(s):  
S.Wynne ELLIS ◽  
Graham P. HAYHURST ◽  
Tracy LIGHTFOOT ◽  
Gillian SMITH ◽  
Jacky HARLOW ◽  
...  

2000 ◽  
Vol 345 (3) ◽  
pp. 565-571 ◽  
Author(s):  
S. Wynne ELLIS ◽  
Graham P. HAYHURST ◽  
Tracy LIGHTFOOT ◽  
Gillian SMITH ◽  
Jacky HARLOW ◽  
...  

Homology models of cytochrome P450 2D6 (CYP2D6) have identified serine 304 as an active-site residue and implicated a putative role for this residue in substrate enantioselectivity and the differential inhibition of enzyme activity by the diastereoisomers quinine and quinidine. The role of serine 304 in selectivity is thought to be achieved through a preferential hydrogen-bond interaction between the hydroxyl group of the residue and one of the stereoisomers of each ligand. We have tested this hypothesis by substituting serine 304 with alanine, a non-hydrogen-bonding residue, and compared the properties of the wild-type and mutant enzymes in microsomes prepared from yeast cells expressing the appropriate cDNA-derived enzyme. The Ser304Ala substitution did not alter the enantioselective oxidation of metoprolol; the O-demethylation reaction remained R-(+)-enantioselective (wild-type, RS, 1.7; mutant, RS, 1.6), whereas α-hydroxylation remained S-(-)-enantioselective (wild-type and mutant, R/S, 0.7). Similarly, the selective oxidation of the R-(+) and S-(-) enantiomers of propranolol to the major 4-hydroxy metabolite was identical with both wild-type and mutant forms of the enzyme (R/S 0.9), although the formation of minor metabolites (5-hydroxy and deisopropylpropranolol) did show some slight alteration in enantioselectivity. The differential inhibition of enzyme activity by quinine and quinidine was also identical with both forms of CYP2D6, the IC50 values for each enzyme being approx. 10 μM and 0.1 μM for quinine and quinidine, respectively. The kinetics of formation of α-hydroxymetoprolol and 4-hydroxydebrisoquine by wild-type and the Ser304Ala mutant was also very similar. However, modest changes in the regioselective oxidation of metoprolol and debrisoquine were observed with the Ser304Ala mutant. The regio- and enantioselective oxidation of an analogue of metoprolol, in which the hydroxyl group attached to the chiral carbon was replaced by a methyl moiety, was again identical with both wild-type and Ser304Ala mutant. However, the observed selectivity was the reverse of that observed with metoprolol. Collectively, these data indicate that Ser304 is unlikely to be a key ligand-binding residue, although the residue may indeed be located in the active-site cavity. The reversal of selectivity with the methyl analogue of metoprolol indicates that the hydroxyl group attached to the chiral centre of ligands, such as metoprolol, is important in defining the enzyme's selective properties, and that a hydrogen-bonding residue, other than Ser304, may be involved in this interaction. Current homology models of the active site of CYP2D6 that predict a hydrogen-bond interaction between Ser304 and specific ligands will need to be re-evaluated, and other candidate residues capable of such an interaction nominated and tested by site-directed mutagenesis studies.


2006 ◽  
Vol 447 (1) ◽  
pp. 53-58 ◽  
Author(s):  
Robert A.B. van Waterschoot ◽  
Peter H.J. Keizers ◽  
Chris de Graaf ◽  
Nico P.E. Vermeulen ◽  
Richard A. Tschirret-Guth

2004 ◽  
Vol 380 (2) ◽  
pp. 353-360 ◽  
Author(s):  
Jack U. FLANAGAN ◽  
Jean-Didier MARÉCHAL ◽  
Richard WARD ◽  
Carol A. KEMP ◽  
Lesley A. McLAUGHLIN ◽  
...  

Although the residues that determine the preference of CYP2D6 (cytochrome P450 2D6) for compounds containing a basic nitrogen are well characterized, the contribution of other active site residues to substrate binding and orientation is less well understood. Our structural model of CYP2D6 identifies the aromatic residue Phe120 as a likely major feature of the active site. To examine the role of Phe120, mutants of CYP2D6 in which this residue has been substituted by alanine, leucine, tyrosine, serine, histidine, tryptophan or methionine residues have been prepared in bacterial membranes co-expressing human cytochrome NADPH cytochrome P450 oxidoreductase. The mutants have been characterized using the prototypical bufuralol 1´ hydroxylase and dextromethorphan O- and N-demethylase activities of CYP2D6. Larger effects on Km values are observed for dextromethorphan O-demethylation than for bufuralol 1´ hydroxylation, indicating that the Phe120 side chain is more important in dextromethorphan than in bufuralol binding. A role for this side chain in determining the regiospecificity of substrate oxidation was indicated by changes in the relative rates of O- and N-demethylation of dextromethorphan and, notably, by the formation of 7-hydroxy dextromethrophan, a novel dextromethorphan metabolite, in mutants in which it had been substituted. Computational studies of dextromethorphan binding to the active site of the Phe120→Ala mutant were carried out to throw light on the way in which the removal of this side chain leads to different modes of ligand binding.


2012 ◽  
Vol 110 ◽  
pp. 46-50 ◽  
Author(s):  
Karel Berka ◽  
Eva Anzenbacherová ◽  
Tereza Hendrychová ◽  
Reinhard Lange ◽  
Vlastimil Mašek ◽  
...  

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
André Fischer ◽  
Martin Smieško

Abstract The membrane-anchored enzyme Cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of around 25% of marketed drugs and its metabolic performance shows a high interindividual variation. While it was suggested that ligands access the buried active site of the enzyme from the membrane, no proof from unbiased simulations has been provided to support this hypothesis. Laboratory experiments fail to capture the access process which is suspected to influence binding kinetics. Here, we applied unbiased molecular dynamics (MD) simulations to investigate the access of ligands to wild-type CYP2D6, as well as the allelic variant CYP2D6*53. In multiple simulations, substrates accessed the active site of the enzyme from the protein-membrane interface to ultimately adopt a conformation that would allow a metabolic reaction. We propose the necessary steps for ligand access and the results suggest that the increased metabolic activity of CYP2D6*53 might be caused by a facilitated ligand uptake.


1995 ◽  
Vol 270 (49) ◽  
pp. 29055-29058 ◽  
Author(s):  
S. Wynne Ellis ◽  
Graham P. Hayhurst ◽  
Gillian Smith ◽  
Tracy Lightfoot ◽  
Mandy M. S. Wong ◽  
...  

2007 ◽  
Vol 36 (6) ◽  
pp. 589-599 ◽  
Author(s):  
Chris de Graaf ◽  
Chris Oostenbrink ◽  
Peter H. J. Keizers ◽  
Barbara M. A. van Vugt-Lussenburg ◽  
Jan N. M. Commandeur ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document